{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:53Z","timestamp":1793394893024,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12072-022-10304-z","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T23:36:10Z","timestamp":1645140970000},"page":"325-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2486-1449","authenticated-orcid":false,"given":"Daljeet","family":"Chahal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Keshavarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhar Ali Qazi","family":"Arisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"10304_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10304_CR2","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901\u2013910","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10304_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.trim.2013.10.006","volume":"30","author":"S Kesiraju","year":"2014","unstructured":"Kesiraju S, Paritala P, Ch UMR, Sahariah S. New onset of diabetes after transplantation\u2014an overview of epidemiology, mechanism of development and diagnosis. Transpl Immunol 2014;30:52\u201358","journal-title":"Transpl Immunol"},{"key":"10304_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547\u2013555","journal-title":"Gastroenterology"},{"key":"10304_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328\u2013357","journal-title":"Hepatology"},{"key":"10304_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/hep4.1519","volume":"4","author":"S Young","year":"2020","unstructured":"Young S, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis. Hepatol Commun 2020;4:953\u2013972","journal-title":"Hepatol Commun"},{"key":"10304_CR7","first-page":"086","volume-title":"Seminars in Liver Disease","author":"R Younes","year":"2019","unstructured":"Younes R, Bugianesi E. NASH in lean individuals. In: Monga S, Bataller R, editors. Seminars in Liver Disease, vol. 39. New York: Thieme Medical Publishers; 2019. p. 086\u201395."},{"key":"10304_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.clnu.2018.08.008","volume":"38","author":"AY Wang","year":"2019","unstructured":"Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr 2019;38:975\u2013981","journal-title":"Clin Nutr"},{"key":"10304_CR9","volume-title":"UK Biobank Data: Come and Get It","author":"NE Allen","year":"2014","unstructured":"Allen NE, Sudlow C, Peakman T, Collins R. UK Biobank Data: Come and Get It. Washington, DC: American Association for the Advancement of Science; 2014"},{"key":"10304_CR10","doi-asserted-by":"publisher","first-page":"e0172921","DOI":"10.1371\/journal.pone.0172921","volume":"12","author":"HR Wilman","year":"2017","unstructured":"Wilman HR, et al. Characterisation of liver fat in the UK Biobank cohort. PLoS One 2017;12:e0172921","journal-title":"PLoS ONE"},{"key":"10304_CR11","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","volume":"29","author":"J Gu","year":"2019","unstructured":"Gu J, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol 2019;29:3564\u20133573","journal-title":"Eur Radiol"},{"key":"10304_CR12","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy C, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 2018;67:1348\u20131359","journal-title":"Hepatology"},{"key":"10304_CR13","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cgh.2017.04.045","volume":"15","author":"AL Fracanzani","year":"2017","unstructured":"Fracanzani AL, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol 2017;15:1604\u20131611","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10304_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/00365521.2014.983160","volume":"50","author":"U Akyuz","year":"2015","unstructured":"Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels. Scand J Gastroenterol 2015;50:341\u2013346","journal-title":"Scand J Gastroenterol"},{"key":"10304_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/MCG.0b013e31826be328","volume":"47","author":"A Margariti","year":"2013","unstructured":"Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2013;47:280\u2013286","journal-title":"J Clin Gastroenterol"},{"key":"10304_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/MPG.0000000000001974","volume":"67","author":"PKC Selvakumar","year":"2018","unstructured":"Selvakumar PKC, et al. Prevalence of suspected nonalcoholic fatty liver disease in lean adolescents in the United States. J Pediatr Gastroenterol Nutr 2018;67:75\u201379","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10304_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00535-014-0948-9","volume":"50","author":"K Nishioji","year":"2015","unstructured":"Nishioji K, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011\u20132012. J Gastroenterol 2015;50:95\u2013108","journal-title":"J Gastroenterol"},{"key":"10304_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.28697","volume":"65","author":"JCF Leung","year":"2017","unstructured":"Leung JCF, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 2017;65:54\u201364","journal-title":"Hepatology"},{"key":"10304_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00004836-200609000-00016","volume":"40","author":"C-H Chen","year":"2006","unstructured":"Chen C-H, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006;40:745\u2013752","journal-title":"J Clin Gastroenterol"},{"key":"10304_CR20","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461\u20131465","journal-title":"Nat Genet"},{"key":"10304_CR21","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1073\/pnas.1901974116","volume":"116","author":"S BasuRay","year":"2019","unstructured":"BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci 2019;116:9521\u20139526","journal-title":"Proc Natl Acad Sci"},{"key":"10304_CR22","doi-asserted-by":"publisher","first-page":"8913","DOI":"10.1073\/pnas.1323785111","volume":"111","author":"H Mahdessian","year":"2014","unstructured":"Mahdessian H, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci 2014;111:8913\u20138918","journal-title":"Proc Natl Acad Sci"},{"key":"10304_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47737-w","volume":"9","author":"S Prill","year":"2019","unstructured":"Prill S, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep 2019;9:1\u201312","journal-title":"Sci Rep"},{"key":"10304_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"Y-L Liu","year":"2014","unstructured":"Liu Y-L, et al. Carriage of the PNPLA3 rs738409 C> G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75\u201381","journal-title":"J Hepatol"},{"key":"10304_CR25","first-page":"1","volume":"5","author":"Y-L Liu","year":"2014","unstructured":"Liu Y-L, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5:1\u20136","journal-title":"Nat Commun"},{"key":"10304_CR26","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s001250100634","volume":"44","author":"M Barbieri","year":"2001","unstructured":"Barbieri M, et al. New aspects of the insulin resistance syndrome: impact on haematological parameters. Diabetologia 2001;44:1232\u20131237","journal-title":"Diabetologia"},{"key":"10304_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.atherosclerosis.2010.08.047","volume":"213","author":"AC Phillips","year":"2010","unstructured":"Phillips AC, et al. Lymphocyte sub-population cell counts are associated with the metabolic syndrome and its components in the Vietnam Experience Study. Atherosclerosis 2010;213:294\u2013298","journal-title":"Atherosclerosis"},{"key":"10304_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/jgh.12580","volume":"29","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Zeng J, Chen B. Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver. J Gastroenterol Hepatol 2014;29:1508\u20131514","journal-title":"J Gastroenterol Hepatol"},{"key":"10304_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.dld.2010.04.005","volume":"42","author":"Y-J Lee","year":"2010","unstructured":"Lee Y-J, et al. Relationship between white blood cell count and nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:888\u2013894","journal-title":"Dig Liver Dis"},{"key":"10304_CR30","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/liv.12226","volume":"33","author":"S Verma","year":"2013","unstructured":"Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013;33:1398\u20131405","journal-title":"Liver Int"},{"key":"10304_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-020-1165-z","volume":"20","author":"X Ma","year":"2020","unstructured":"Ma X, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:1\u20138","journal-title":"BMC Gastroenterol"},{"key":"10304_CR32","doi-asserted-by":"crossref","unstructured":"Moon S-S. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009\u20132010. Endocr J 2013:EJ13\u20130244","DOI":"10.1507\/endocrj.EJ13-0244"},{"key":"10304_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.diabet.2017.04.005","volume":"43","author":"S Kashima","year":"2017","unstructured":"Kashima S, Inoue K, Matsumoto M, Akimoto K. Low serum creatinine is a type 2 diabetes risk factor in men and women: the Yuport Health Checkup Center cohort study. Diabetes Metab 2017;43:460\u2013464","journal-title":"Diabetes Metab"},{"key":"10304_CR34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/hep.26716","volume":"59","author":"HC Hong","year":"2014","unstructured":"Hong HC, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014;59:1772\u20131778","journal-title":"Hepatology"},{"key":"10304_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/hepr.13429","volume":"50","author":"T Okamura","year":"2020","unstructured":"Okamura T, et al. Creatinine-to-bodyweight ratio is a predictor of incident non-alcoholic fatty liver disease: a population-based longitudinal study. Hepatol Res 2020;50:57\u201366","journal-title":"Hepatol Res"},{"key":"10304_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younossi","year":"2012","unstructured":"Younossi ZM, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012;91:319\u2013327","journal-title":"Medicine"},{"key":"10304_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5009\/gnl14444","volume":"10","author":"HC Cho","year":"2016","unstructured":"Cho HC. Prevalence and factors associated with nonalcoholic fatty liver disease in a nonobese Korean population. Gut Liver 2016;10:117","journal-title":"Gut Liver"},{"key":"10304_CR38","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/ajg.2012.314","volume":"107","author":"Y-M Kwon","year":"2012","unstructured":"Kwon Y-M, et al Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults Am J Gastroenterol 2012;107:1852\u20131858","journal-title":"Am J Gastroenterol"},{"key":"10304_CR39","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3748\/wjg.v21.i5.1650","volume":"21","author":"Q Pang","year":"2015","unstructured":"Pang Q, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol WJG 2015;21:1650","journal-title":"World J Gastroenterol WJG"},{"key":"10304_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/j.1440-1746.2007.05212.x","volume":"23","author":"BJ Park","year":"2008","unstructured":"Park BJ, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol 2008;23:900\u2013907","journal-title":"J Gastroenterol Hepatol"},{"key":"10304_CR41","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1053\/j.gastro.2006.03.041","volume":"130","author":"P Angulo","year":"2006","unstructured":"Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 2006;130:1848\u20131852","journal-title":"Gastroenterology"},{"key":"10304_CR42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cgh.2015.07.024","volume":"14","author":"D Kim","year":"2016","unstructured":"Kim D, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:132\u2013138","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10304_CR43","doi-asserted-by":"publisher","first-page":"e2159","DOI":"10.1097\/MD.0000000000002159","volume":"94","author":"SJ Yu","year":"2015","unstructured":"Yu SJ, et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine 2015;94:e2159","journal-title":"Medicine"},{"key":"10304_CR44","doi-asserted-by":"publisher","first-page":"E1756","DOI":"10.1210\/jc.2011-0615","volume":"96","author":"T McLaughlin","year":"2011","unstructured":"McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab 2011;96:E1756\u2013E1760","journal-title":"J Clin Endocrinol Metab"},{"key":"10304_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/liv.14347","volume":"40","author":"L Castera","year":"2020","unstructured":"Castera L. Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics. Liver Int 2020;40:77\u201381","journal-title":"Liver Int"},{"key":"10304_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-75227-x","volume":"10","author":"V Blank","year":"2020","unstructured":"Blank V, et al. Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Sci Rep 2020;10:1\u201311","journal-title":"Sci Rep"},{"key":"10304_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/liv.13970","volume":"39","author":"F Procino","year":"2019","unstructured":"Procino F, et al. Reducing NAFLD-screening time: a comparative study of eight diagnostic methods offering an alternative to ultrasound scans. Liver Int 2019;39:187\u2013196","journal-title":"Liver Int"},{"key":"10304_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3748\/wjg.v19.i1.57","volume":"19","author":"S Zelber-Sagi","year":"2013","unstructured":"Zelber-Sagi S, et al. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol WJG 2013;19:57","journal-title":"World J Gastroenterol WJG"},{"key":"10304_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:1\u20137","journal-title":"BMC Gastroenterol"},{"key":"10304_CR50","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk L, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209\u20131222","journal-title":"Aliment Pharmacol Ther"},{"key":"10304_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"J-H Lee","year":"2010","unstructured":"Lee J-H, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503\u2013508","journal-title":"Dig Liver Dis"},{"key":"10304_CR52","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/liv.13941","volume":"38","author":"C Xu","year":"2018","unstructured":"Xu C, et al. Visceral adiposity index as a predictor of NAFLD: a prospective study with 4-year follow-up. Liver Int 2018;38:2294\u20132300","journal-title":"Liver Int"},{"key":"10304_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-016-0392-3","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis 2017;16:1\u20138","journal-title":"Lipids Health Dis"},{"key":"10304_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhep.2020.03.032","volume":"73","author":"CA Parisinos","year":"2020","unstructured":"Parisinos CA, et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241\u2013251","journal-title":"J Hepatol"},{"key":"10304_CR55","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14548","volume":"40","author":"S Lin","year":"2020","unstructured":"Lin S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:2082\u20132089","journal-title":"Liver Int"},{"key":"10304_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739\u2013752","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10304-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10304-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10304-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T19:06:42Z","timestamp":1668020802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10304-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10304"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10304-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"5 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daljeet Chahal: No conflicts of interest to disclose. Divya Sharma: No conflicts of interest to disclose. Sareh Keshavarzi: No conflicts of interest to disclose. Fakhar Ali Qazi Arisar: No conflicts of interest to disclose. Keyur Patel: No conflicts of interest to disclose. Wei Xu: No conflicts of interest to disclose. Mamatha Bhat: No conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The UK biobank has approval from the Northwest multicenter research ethics committee and written informed consent had been obtained from all participants prior to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have consented to the publication of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}